Loading
Led FLAIR, the UK trial showing MRD-guided ibrutinib plus venetoclax outperforms chemoimmunotherapy in CLL.
Peter Hillmen (Leeds) was chief investigator of the UK NCRI FLAIR trial, which showed ibrutinib plus venetoclax with MRD-guided duration improves progression-free and overall survival compared with FCR in untreated CLL, and of the CLARITY trial that first tested this combination. He led the UK CLL trials group for two decades and was also central to the development of eculizumab for PNH.
| Title | Journal | Year |
|---|---|---|
| Ibrutinib plus venetoclax with MRD-directed duration of treatment is superior to FCR and is a new standard of care for previously untreated CLL (FLAIR) | NEJM | 2024 |
| Ibrutinib plus venetoclax in relapsed/refractory chronic lymphocytic leukemia: the CLARITY study | JCO | 2019 |
Shares BCL-2, Venetoclax, MRD / molecular residual disease testing, Chronic lymphocytic leukaemia and the tag cll.
Shares BCL-2, Venetoclax, MRD / molecular residual disease testing, Chronic lymphocytic leukaemia and the tag cll.
Shares BCL-2, Venetoclax, MRD / molecular residual disease testing, Chronic lymphocytic leukaemia and the tag cll.
Shares BCL-2, Venetoclax, MRD / molecular residual disease testing, Chronic lymphocytic leukaemia and the tag cll.
Shares BCL-2, Venetoclax, Chronic lymphocytic leukaemia, Small-molecule kinase inhibitors and the tag cll.
Shares Venetoclax, Chronic lymphocytic leukaemia, Small-molecule kinase inhibitors.
Shares Chronic lymphocytic leukaemia, Small-molecule kinase inhibitors and the tag cll.
Shares BCL-2, Venetoclax, MRD / molecular residual disease testing.